Sign in

OCS on Nasdaq

Oculis Holding AG

Oculis Holding AG is a stock corporation.1 Its shares trade on Nasdaq under the symbol OCS.1

Price unavailable

Last updated Oct 21, 2026.

Overview

-99.0MNet income, fiscal 20252

Compare with another stock.

  • TickerOCS on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersV81
  • Incorporated inSwitzerland3
  • Business addressBahnhofstrasse 7, Zug, V8 63003
  • Filer categoryLarge accelerated filer3

See how the biggest companies compare on our leaderboards

We are a stock corporation ( Aktiengesellschaft ) that was incorporated under the laws of Switzerland on October 31, 2022. We are registered with the commercial register of the Canton of Zug under company registration number CHE-396.695.611 . The mailing address of our principal executive office is Oculis Holding AG, Bahnhofstrasse 20, CH-6300, Zug, Switzerland. Neither our articles of association nor the operation of law limit our duration.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-50.5%Return on equity2
-$66.6MFree cash flow2

Financial statements

Operating income5672-$81.7M in 2025+562% since 2020
-$100.0M-$75.0M-$50.0M-$25.0M02020: -$12.3M-$12.3M20202021: -$13.2M-$13.2M2021+7%2022: -$32.4M-$32.4M2022+145%2023: -$80.7M-$80.7M2023+149%2024: -$73.2M-$73.2M2024−9%2025: -$81.7M-$81.7M2025+12%
Net income5672-$99.0M in 2025+565% since 2020
-$100.0M-$75.0M-$50.0M-$25.0M02020: -$14.9M-$14.9M20202021: -$18.6M-$18.6M2021+25%2022: -$38.7M-$38.7M2022+109%2023: -$88.8M-$88.8M2023+129%2024: -$85.8M-$85.8M2024−3%2025: -$99.0M-$99.0M2025+15%

Every line of the income statement as filed: the last 3 fiscal years, latest first.2

Period ending2025-12-312024-12-312023-12-31
Grant income1.2M CHF686.0K CHF883.0K CHF
Operating income1.2M CHF686.0K CHF883.0K CHF
Research and development expenses-57.1M CHF-52.1M CHF-29.2M CHF
General and administrative expenses-25.8M CHF-21.8M CHF-17.5M CHF
Merger and listing expense-34.9M CHF
Operating expenses-82.9M CHF-73.9M CHF-81.6M CHF
Operating loss-81.7M CHF-73.2M CHF-80.7M CHF
Finance income1.8M CHF2.2M CHF1.4M CHF
Finance expense-833.0K CHF-639.0K CHF-1.3M CHF
Fair value adjustment on warrant liabilities-12.3M CHF-15.5M CHF-3.4M CHF
Foreign currency exchange gain (loss)-6.1M CHF1.3M CHF-4.7M CHF
Finance result-17.5M CHF-12.7M CHF-8.0M CHF
Loss before tax for the period-99.1M CHF-85.9M CHF-88.7M CHF
Income tax benefit (expense)186.0K CHF160.0K CHF-107.0K CHF
Loss for the period-99.0M CHF-85.8M CHF-88.8M CHF
Basic, loss attributable to equity holders-1.89 CHF-2.12 CHF-2.97 CHF
Diluted, loss attributable to equity holders-1.89 CHF-2.12 CHF-2.97 CHF

Compare Oculis Holding AG with another company

Corporate structure

Oculis Holding AG sits at the top of its group. 1 entity on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Oculis Holding AG

  • 7. Cooperative Ua Lsp Filed SCHEDULE 13G/A on Oculis Holding AG, latest Apr 29, 2026 (3 filings since Feb 9, 2024)
  • BVCF IV, L.P. Filed SCHEDULE 13G/A on Oculis Holding AG, latest Mar 27, 2026 (3 filings since May 2, 2023)
  • Pivotal bioVenture Partners Fund I, L.P. Filed SCHEDULE 13G/A on Oculis Holding AG, latest Nov 14, 2025 (5 filings since Mar 15, 2023)
  • Vaxtarsjodur Slhf Brunnur Filed SCHEDULE 13G/A on Oculis Holding AG, latest Jan 3, 2025 (2 filings since May 4, 2023)
  • Novartis Bioventures Ltd Filed SC 13G/A on Oculis Holding AG, latest Feb 13, 2024 (2 filings since Mar 13, 2023)
  • Oculis Holding AG V8

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Oculis Holding AG reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, net534.0K CHF2 Dec 31, 2025385.0K CHF2 Dec 31, 2024+38.7%
Operating-lease assets (leased space)2.5M CHF2 Dec 31, 20251.3M CHF2 Dec 31, 2024+89.0%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents81.3M CHF2 Dec 31, 202527.7M CHF2 Dec 31, 2024+193.5%
Long-term investments249.0K CHF2 Dec 31, 2025141.0K CHF2 Dec 31, 2024+76.6%

Intangibles and goodwill

ItemLatestA year beforeChange
Intangible assets, net (excluding goodwill)13.3M CHF2 Dec 31, 202513.3M CHF2 Dec 31, 20240%

Calendar

Coming up

  1. Nov 9, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.40) a share, on Nov 10, 2025.8

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

136 filings to the SEC since October 2021: 5 annual reports, 15 large holders, 116 other. The latest 20:

  1. Sep 30, 20266-K EDGAR
  2. Aug 10, 20266-K EDGAR
  3. Aug 6, 2026S-8 EDGAR
  4. Aug 6, 20266-K EDGAR
  5. Jun 25, 20266-K EDGAR
  6. Jun 1, 20266-K EDGAR
  7. May 14, 20266-K EDGAR
  8. May 11, 20266-K EDGAR
  9. Apr 29, 2026SCHEDULE 13G/A EDGAR
  10. Apr 21, 20266-K EDGAR
  11. Mar 27, 2026SCHEDULE 13G/A EDGAR
  12. Mar 9, 2026144 EDGAR
  13. Mar 4, 20266-K EDGAR
  14. Mar 4, 2026F-3ASR EDGAR
  15. Mar 4, 202620-F EDGAR
  16. Mar 3, 20266-K EDGAR
  17. Dec 8, 2025EFFECT EDGAR
  18. Dec 5, 2025POS AM EDGAR
  19. Dec 1, 2025424B3 EDGAR
  20. Nov 14, 2025SCHEDULE 13G/A EDGAR

The 136 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How Oculis Holding AG is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGAROculis Holding AG1
  • CIK0001953530
  • Filer statusLarge accelerated filer not an emerging growth company; not a shell company4
  • Incorporated inSwitzerland4
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business addressBahnhofstrasse 7, Zug, V8 63001
  • Phone617-937-24231
  • Shares outstanding57,984,438 Ordinary Shares shares; 2,104,906 Warrants shares as of Dec 31, 20254
  • AuditorPricewaterhouseCoopers SA, Lausanne, Switzerland PCAOB ID 1358; it also attests to the company’s internal control over financial reporting4
  • On EDGAR sinceNov 7, 20221
  • Filings136 in all: 6-K (46), 424B3 (12), CORRESP (11), UPLOAD (8), EFFECT (7), SC 13G (6), SCHEDULE 13G/A (6), 20-F (5)1
    All 24 form types

    424B5 (5), 144 (4), F-4/A (4), F-3 (3), S-8 (3), SC 13G/A (3), F-1 (2), POS AM (2), SEC STAFF LETTER (2), 424B4 (1), 8-A12B (1), CERT (1), DRS (1), F-1/A (1), F-3ASR (1), F-4 (1)

  • Latest filingsAnnual report (20-F) Mar 4, 2026

Securities registered for trading

ClassSymbolExchange
Ordinary SharesOCSThe Nasdaq Stock Market LLC
WarrantsOCSAWThe Nasdaq Stock Market LLC

From the cover page of the 20-F filed Mar 4, 2026 (Section 12(b) of the Exchange Act).4

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13